NCT02051062

BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin

• Status: Enrolling By Invitation
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Emergent BioSolutions · Industry
• Sex: All
• Age: 1 Day – 11 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to verify the pediatric dosing recommendations for BAT product in pediatric patients that are treated with BAT product due to a confirmed or suspected case of botulism. A minimum of one serum sample should be collected but whenever feasible additional serum samples (up to three per enrolled participant) may be collected from the participant or obtained from surplus standard of care samples, if available, within 32 hours after BAT product administration. Safety of the BAT product will also be evaluated. Emergent will follow-up with the physician by telephone after 30 days post-BAT product administration to collect AEs, SAEs, and unanticipated events.

Detailed description

Primary Objective: To collect blood from pediatric participants to analyze the pharmacokinetics (PK) of BAT product to verify the current US FDA-approved pediatric dosing recommendations for BAT product. Safety Objective: To evaluate the safety of BAT product in pediatric participants. Protocol Design: This is a single arm, multi-site PK study in pediatric patients treated with BAT product. Pharmacokinetic Parameters: The serum concentrations of BAT product obtained will be modeled using a population PK approach based on a previously developed model for BAT serotypes A through G in healthy adult human participants. Safety Endpoints: The incidence of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) that occur within 30 days after BAT product administration. In this study hypersensitivity/allergic reactions including serum sickness, febrile reactions, and hemodynamic instability and bradycardia, as well as reports of an infectious disease transmission will be included as AESI.

Conditions

• Botulism

Interventions

Type	Name	Description
BIOLOGICAL	Blood sample collection	One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.

Timeline

• Start date: 2014-10-01
• Primary completion: 2028-07-31
• Completion: 2028-07-31
• First posted: 2014-01-31
• Last updated: 2026-01-16

Regulatory

• FDA-regulated drug study